GBV-C infection and risk of NHL among U.S. adults

Cancer Research

Volumn 74, Issue 19, 2014, Pages 5553-5560

  Chang, Cindy M ^a,c   Stapleton, Jack T ^b   Klinzman, Donna ^b   McLinden, James H ^b   Purdue, Mark P ^a   Katki, Hormuzd A ^a   Engels, Eric A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c CENTER FOR TOBACCO PRODUCTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PRIMER DNA;

AGED; CASE CONTROL STUDY; COMPLICATION; FEMALE; FLAVIVIRIDAE INFECTION; GENETICS; HEPATITIS G VIRUS; HUMAN; ISOLATION AND PURIFICATION; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK FACTOR; UNITED STATES; VIROLOGY; VIRUS HEPATITIS;

AGED; BASE SEQUENCE; CASE-CONTROL STUDIES; DNA PRIMERS; FEMALE; FLAVIVIRIDAE INFECTIONS; GB VIRUS C; HEPATITIS, VIRAL, HUMAN; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK FACTORS; UNITED STATES;

EID: 84907494582     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0209     Document Type: Article

References (47)

1. Adams MJ, King AMQ, Carstens EB. Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2013). Arch Virol 2013;158:2023-30.
2. Linnen J, Wages J Jr, Zhang-Keck ZY, Fry KE, Krawczynski KZ, Alter H, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996;271:505-8.
3. Simons JN, Pilot-Matias TJ, Leary TP, Dawson GJ, Desai SM, Schlauder GG, et al. Identification of two flavivirus-like genomes in the GB hepatitis agent. Proc Natl Acad Sci U S A 1995;92:3401-5.
4. Reshetnyak VI, Karlovich TI, Ilchenko LU. Hepatitis G virus. World J Gastroenterol 2008;14:4725-34.
5. George SL, Wunschmann S, McCoy J, Xiang J, Stapleton JT. Interactions between GB virus type C and HIV. Curr Infect Dis Rep 2002;4:550-8.
6. Lefrere JJ, Ferec C, Roudot-Thoraval F, Loiseau P, Cantaloube JF, Biagini P, et al. GBV-C/hepatitis G virus (HGV) RNA load in immunodeficient individuals and in immunocompetent individuals. J Med Virol 1999;59:32-7.
7. SEER Cancer Statistics Review, 1975-2011 [Internet]. Bethesda, MD: National Cancer Institute; [updated 2014 April; cited 2014 May]. Available from: http://www.seer.cancer.gov/csr/1975-2011.
8. Hartge P, Bracci PM, Wang SS, Devesa SS, Holly EA, Schottenfeld D, et al. Non-Hodgkin lymphoma. Cancer epidemiology and prevention. 3rd ed. Oxford, United Kingdom: Oxford Press; 2006.
9. Hjalgrim H, Engels EA. Infectious aetiology of Hodgkin and non-Hodgkin lymphomas: a review of the epidemiological evidence. J Intern Med 2008;264:537-48.
10. Radkowski M, Kubicka J, Kisiel E, Cianciara J, Nowicki M, Rakela J, et al. Detection of active hepatitis C virus and hepatitis G virus/GB virus C replication in bone marrow in human subjects. Blood 2000;95:3986-9.
11. Tucker TJ, Smuts HE, Eedes C, Knobel GD, Eickhaus P, Robson SC, et al. Evidence that the GBV-C/hepatitis G virus is primarily a lymphotropic virus. J Med Virol 2000;61:52-8.
12. Fogeda M, Navas S, Martin J, Casqueiro M, Rodriguez E, Arocena C, et al. In vitro infection of human peripheral blood mononuclear cells by GB virus C/hepatitis G virus. J Virol 1999;73:4052-61.
13. George SL, Varmaz D, Stapleton JT. GB virus C replicates in primary T and B lymphocytes. J Infect Dis 2006;193:451-4.
14. Moenkemeyer M, Schmidt RE, Wedemeyer H, Tillmann HL, Heiken H. GBV-C coinfection is negatively correlated to Fas expression and Fasmediated apoptosis in HIV-1 infected patients. J Med Virol 2008;80:1933-40.
15. Stapleton JT, Chaloner K, Martenson JA, Zhang J, Klinzman D, Xiang J, et al. GB virus C infection is associated with altered lymphocyte subset distribution and reduced T cell activation and proliferation in HIV-infected individuals. PLoS ONE 2012;7:e50563.
16. Rydze RT, Bhattarai N, Stapleton JT. GB virus C infection is associated with a reduced rate of reactivation of latent HIV and protection against activation-induced T-cell death. Antivir Ther 2012;17:1271.
17. Krajden M, Yu A, Braybrook H, Lai AS, Mak A, Chow R, et al. GBV-C/hepatitis G virus infection and non-Hodgkin lymphoma: a case control study. Int J Cancer 2010;126:2885-92.
18. Civardi G, Tanzi E, Ferrari B, Vallisa D, Zanetti A, Cavanna L. High prevalence of anti-HGV/E2 antibodies in HCV-positive patients with non Hodgkin's lymphoma. Haematologica 1998;83:957-8.
19. Collier JD, Zanke B, Moore M, Kessler G, Krajden M, Shepherd F, et al. No association between hepatitis C and B-cell lymphoma. Hepatology 1999;29:1259-61.
20. De Renzo A, Persico E, de Marino F, di Giacomo Russo G, Notaro R, di Grazia C, et al. High prevalence of hepatitis G virus infection in Hodgkin's disease and B-cell lymphoproliferative disorders: absence of correlation with hepatitis C virus infection. Haematologica 2002;87:714-8.
21. Giannoulis E, Economopoulos T, Mandraveli K, Giannoulis K, Nikolaides C, Zervou E, et al. The prevalence of hepatitis C and hepatitis G virus infection in patients with B cell non-Hodgkin lymphomas in Greece: a Hellenic CooperativeOncology GroupStudy. ActaHaematol 2004;112:189-93.
22. Kaya H, Polat MF, Erdem F, Gundogdu M. Prevalence of hepatitis C virus and hepatitis G virus in patients with non-Hodgkin's lymphoma. Clin Lab Haematol 2002;24:107-10.
23. Minton J, Iqbal A, Eskiturk A, Irving W, Davies J. Hepatitis G virus infection in lymphoma and in blood donors. J Clin Pathol 1998;51:676-8.
24. Zignego AL, Giannini C, Gentilini P, Bellesi G, Hadziyannis S, Ferri C. Could HGV infection be implicated in lymphomagenesis? Br J Haematol 1997;98:778-9.
25. Prorok PC, Andriole GL, Bresalier RS, Buys SS, Chia D, Crawford ED, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials 2000;21:273S-309S.
26. Souza IE, Allen JB, Xiang J, Klinzman D, Diaz R, Zhang S, et al. Effect of primer selection on estimates of GB virus C (GBV-C) prevalence and response to antiretroviral therapy for optimal testing for GBV-C viremia. J Clin Microbiol 2006;44:3105-13.
27. Stapleton JT, Chaloner K, Zhang J, Klinzman D, Souza IE, Xiang J, et al. GBV-C viremia is associated with reduced CD4 expansion in HIV-infected people receiving HAART and interleukin-2 therapy. Aids 2009;23:605-10.
28. Xiang J, Wunschmann S, Schmidt W, Shao J, Stapleton JT. Full-length GB virus C (Hepatitis G virus) RNA transcripts are infectious in primary CD4-positive T cells. J Virol 2000;74:9125-33.
29. Bhattarai N, McLinden JH, Xiang J, Kaufman TM, Stapleton JT. GB virus C envelope protein E2 inhibits TCR-induced IL-2 production and alters IL-2-signaling pathways. J Immunol 2012;189:2211-6.
30. Taylor JW. Simple estimation of population attributable risk from casecontrol studies. Am J Epidemiol 1977;106:260.
31. Nordbo SA, Krokstad S, Winge P, Skjeldestad FE, Dalen AB. Prevalence of GBvirusC (also calledhepatitis G virus) markers in Norwegian blood donors. J Clin Microbiol 2000;38:2584-90.
32. Oliveira LA, Martins R, Carneiro MA, Teles SA, Silva SA, Cardoso DD, et al. Prevalence and genotypes of GB virus C/hepatitis G virus among blood donors in Central Brazil. Mem Inst Oswaldo Cruz 2002;97:953-7.
33. Polgreen PM, Xiang J, Chang Q, Stapleton JT. GB virus type C/hepatitis G virus: a non-pathogenic flavivirus associated with prolonged survival in HIV-infected individuals. Microbes Infect 2003;5:1255-61.
34. Stapleton JT, Foung S, Muerhoff AS, Bukh J, Simmonds P. The GB viruses: a review and proposed classification of GBV-A, GBV-C (HGV), and GBV-D in genus Pegivirus within the family Flaviviridae. J Gen Virol 2011;92:233-46.
35. Little SJ, McLean AR, Spina CA, Richman DD, Havlir DV. Viral dynamics of acute HIV-1 infection. J Exp Med 1999;190:841-50.
36. Mohr EL, Xiang J, McLinden JH, Kaufman TM, Chang Q, Montefiori DC, et al. GB virus type C envelope protein E2 elicits antibodies that react with a cellular antigen on HIV-1 particles and neutralize diverse HIV-1 isolates. J Immunol 2010;185:4496-505.
37. Tacke M, Kiyosawa K, Stark K, Schlueter V, Ofenloch-Haehnle B, Hess G, et al. Detection of antibodies to a putative hepatitis G virus envelope protein. Lancet 1997;349:318-20.
38. Thomas DL, Vlahov D, Alter HJ, Hunt JC, Marshall R, Astemborski J, et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis 1998;177:539-42.
39. Matsuo K, Kusano A, Sugumar A, Nakamura S, Tajima K, Mueller NE. Effect of hepatitis C virus infection on the risk of non-Hodgkin's lymphoma: a meta-analysis of epidemiological studies. Cancer Sci 2004;95:745-52.
40. Anderson LA, Engels EA. Hepatitis C virus infection and non-Hodgkin lymphoma: interesting association or causal relationship? Int J Cancer 2008;122:x-xii.
41. de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol 2008;6:451-8.
42. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, et al. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc NatlAcadSci U S A 2004;101:4262-7.
43. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, et al. Binding of hepatitis C virus to CD81. Science 1998;282:938-41.
44. Rosa D, Saletti G, De Gregorio E, Zorat F, Comar C, D'Oro U, et al. Activation of naive B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A 2005;102:18544-9.
45. Stapleton JT, Martinson JA, Klinzman D, Xiang J, Desai SN, Landay A. GB virus C infection and B-cell, natural killer cell, and monocyte activation markers in HIV-infected individuals. Aids 2013;27:1829-32.
46. Bhattarai N, McLinden JH, Xiang J, Landay AL, Chivero ET, Stapleton JT. GB virus C particles inhibit T cell activation via envelope E2 proteinmediated inhibition of TCR signaling. J Immunol 2013;190:6351-9.
47. Bhattarai N, Stapleton JT. GB virus C: the good boy virus? Trends Microbiol 2012;20:124-30.